Back to top
more

Orthofix Medical (OFIX)

(Real Time Quote from BATS)

$15.04 USD

15.04
159,005

-0.07 (-0.46%)

Updated May 17, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Trina Mukherjee headshot

Coronavirus Hits Elective Procedures: 3 MedTech Stocks to Avoid

by Trina Mukherjee

Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.

Orthofix Supports FDA Class III Label Continuation for BGS

by Zacks Equity Research

Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.

Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline

by Zacks Equity Research

We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.

Orthofix (OFIX) Q4 Earnings Match Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 0.00% and -1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -21.15% and -4.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

3D Printing Gaining Popularity: 3 MedTech Stocks to Watch

by Trina Mukherjee

In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down

by Zacks Equity Research

Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

Orthofix (OFIX) Q2 Earnings Miss Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -30.00% and 0.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

Will MedTech Ease Investors' Concern & Outperform? 4 Picks

by Urmimala Biswas

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

Orthofix (OFIX) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -32.50% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Reports Encouraging M6-C Disc Study Results

by Zacks Equity Research

The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.

Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

by Zacks Equity Research

Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?

by Zacks Equity Research

Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.

Nitish Marwah headshot

New Strong Buy Stocks for December 14th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Orthofix (OFIX) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for October 31st

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Orthofix (OFIX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 35.14% and 1.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q3 Earnings Preview: What to Know Ahead of the Release

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 1st

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut

    by Zacks Equity Research

    Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.

      FDA Nod for Orthofix's G-Beam to Boost Extremity Fixation SBU

      by Zacks Equity Research

      Orthofix's (OFIX) latest receipt of FDA approval expected to enhance the Extremity Fixation portfolio.

        What's Driving Orthofix International to a New 52-Week High

        by Zacks Equity Research

        Orthofix International is (OFIX) strong on recent buyouts as well as the FDA approval.

          Orthopedic Device Market Gains Momentum: 3 Stocks in Focus

          by Zacks Equity Research

          The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.